Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors
https://www.facingourrisk.org/research-clinical-trials/study/105/nous-209-genetic-vaccine-for-the-treatment-of-msi-h-colorectal-gastric-and-gastro-esophageal-junction-tumors
Clinicaltrials.gov identifier:
NCT04041310 (https://clinicaltrials.gov/show/NCT04041310)
Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors
Study Contact Information:
Questions about the study can be directed to the study contacts listed below or to Dr. Patricia Delaite at [email protected]
About the Study
The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). NOTE: This study is no longer enrolling people.
This Study is Open To:
NOTE: This study is no longer enrolling people.
This Study is Not Open To:
NOTE: This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.